Interestingly, this was in the opposite direction to RA patients in the same study, whilst a Crohn’s disease cohort also found biological response to infliximab was lower in patients carrying TNFR1 36G mutation in the TNFR1 gene [14]. The gene discussed is TNFRSF1A; the disease is rheumatoid arthritis.